Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Medicines Co. Plans Mid-2013 Regulatory Submissions For Two Key R&D Assets

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicines Co is capitalizing on trends prevalent in both the biopharma industry and its customer base to build one of the fastest- growing specialty pharma franchises. Results for 2012 confirm the strategy has worked to date.

You may also be interested in...



The Medicines Co. Enters PCSK9 Race With Alnylam Deal

The Medicines Company and RNAi therapeutics company Alnylam have teamed up to develop a new drug targeting PCSK9 for the treatment of high cholesterol, but they are far behind the leaders in the pack and will have to differentiate their product from the others in the race.

Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value

Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.

The Medicines Co.’s Cangrelor Rises From The Ashes Of Phase III

TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel